Anavex Life Sciences (AVXL) Non-Current Assets (2011 - 2019)
Anavex Life Sciences (AVXL) reported Non-Current Assets of $151133.0 for Q2 2019, up 188.44% on a YoY basis from $52396.0 in Q2 2018, and down 1.56% sequentially from $153529.0 in Q3 2018.
Anavex Life Sciences (AVXL) Non-Current Assets (2011 - 2019) Analysis & Trends
Anavex Life Sciences (AVXL) has 9 years of Non-Current Assets data on file, last reported at $151133.0 in Q2 2019.
- For the quarter ending Q2 2019, Non-Current Assets rose 188.44% year-over-year to $151133.0; the trailing twelve-month figure through Jun 2020 stood at $151133.0 (down 50.39% YoY), and the FY2018 full-year result was $153529.0, up 193.02% from the prior year.
- Non-Current Assets fell to $151133.0 in Q2 2019, from $153529.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $153529.0 in Q3 2018 to a low of $1501.0 in Q2 2015.
- A 5-year average of $65323.1 and a median of $52396.0 in 2016 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets plunged 99.87% in 2015 and surged 193.02% in 2018, its largest moves.
- Tracing AVXL's Non-Current Assets over 5 years: stood at $1501.0 in 2015, then surged by 3390.74% to $52396.0 in 2016, then changed by 0.0% to $52396.0 in 2017, then surged by 193.02% to $153529.0 in 2018, then decreased by 1.56% to $151133.0 in 2019.
- Business Quant data shows AVXL's Non-Current Assets at $151133.0 in Q2 2019, $153529.0 in Q3 2018, and $52396.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 151,133.00 |
| Sep 30, 2018 | 153,529.00 |
| Jun 30, 2018 | 52,396.00 |
| Mar 31, 2018 | 83,339.00 |
| Dec 31, 2017 | 52,396.00 |
| Sep 30, 2017 | 52,396.00 |
| Jun 30, 2017 | 52,396.00 |
| Sep 30, 2016 | 52,396.00 |
| Jun 30, 2015 | 1,501.00 |
| Mar 31, 2015 | 1,749.00 |
| Dec 31, 2014 | 1,998.00 |
| Sep 30, 2014 | 2,247.00 |
| Jun 30, 2014 | 1.12 Mn |
| Mar 31, 2014 | 1.07 Mn |
| Dec 31, 2013 | 2,135.00 |
| Dec 31, 2012 | 111.00 |
| Sep 30, 2012 | 576.00 |
| Jun 30, 2012 | 1,040.00 |
| Mar 31, 2012 | 1,505.00 |
| Sep 30, 2011 | 2,434.00 |